Diabetes drug could be new hope for failing hearts in lung disease
NCT ID NCT06992440
Summary
This study is testing if a medication called empagliflozin, already used for diabetes and heart failure, can help improve heart function in people with pulmonary arterial hypertension (PAH). About 78 adults with PAH who are already on stable treatment will take either the drug or a placebo pill daily for six months. Researchers will use heart scans and walking tests to see if the drug makes the heart work better and improves patients' health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.